- Home
- ETON
as 04-01-2025 4:00pm EST
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | DEER PARK |
| Market Cap: | 329.8M | IPO Year: | 2018 |
| Target Price: | $27.67 | AVG Volume (30 days): | 222.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.15 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.03 - $18.41 | Next Earning Date: | 03-18-2025 |
| Revenue: | $39,011,000 | Revenue Growth: | 23.29% |
| Revenue Growth (this year): | 107.69% | Revenue Growth (next year): | 65.50% |
Latest Eton Pharmaceuticals Inc. News
ETON Breaking Stock News: Dive into ETON Ticker-Specific Updates for Smart Investing
MT Newswires
21 hours ago
Eton Pharmaceuticals Agrees to License International Rights for Increlex to Esteve Pharmaceuticals
GlobeNewswire
a day ago
Eton Pharmaceuticals Out-Licenses International Rights to Increlex®
GuruFocus.com
11 days ago
Eton Pharmaceuticals Inc (ETON) Q4 2024 Earnings Report Preview: What To Expect
Simply Wall St.
14 days ago
Eton Pharmaceuticals Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Zacks
15 days ago
Eton Pharmaceuticals, Inc. (ETON) Reports Q4 Loss, Tops Revenue Estimates
GlobeNewswire
15 days ago
Eton Pharmaceuticals Reports Fourth Quarter 2024 Financial Results
MT Newswires
19 days ago
Eton's Diabetes Drug Candidate Passes Bioequivalence Study
GlobeNewswire
19 days ago
Eton Pharmaceuticals Announces Positive Pivotal Clinical Study Results for Product Candidate ET-600
Compare ETON vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ETON Eton Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.